SNSS - Sunesis Pharmaceuticals, Inc.
| Previous Close | 0.5887 |
| Open | 0.5010 |
| Bid | 0.500 x 1000 |
| Ask | 0.530 x 1200 |
| Day's Range | 0.4720 - 0.5400 |
| 52 Week Range | 0.2000 - 7.6900 |
| Volume | 3,214,868 |
| Avg. Volume | 370,977 |
| Market Cap | 17.663M |
| Beta (3Y Monthly) | 3.34 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.800 |
| Earnings Date | Mar 7, 2018 - Mar 12, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 0.50 |
- Benzinga•17 hours ago
The Daily Biotech Pulse: Regulatory Roadblock For Immunomedics, AdCom Split On Lexicon's Diabetes Drug
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Jan. 17) Avenue Therapeutics Inc (NASDAQ: ATXI ) BioSpecifics ...
- GlobeNewswire•yesterday
Sunesis Announces Pricing of $20 Million Offering of Securities
Sunesis Pharmaceuticals, Inc. (SNSS) today announced the pricing of underwritten public offerings of (i) 23,000,000 shares of its common stock and (ii) 17,000 shares of its non-voting Series E Convertible Preferred Stock (“Series E Stock”). The public offering price of each share of common stock is $0.50 and the public offering price of each share of Series E Stock, convertible into 1,000 shares of common stock, is $500. Sunesis has granted the underwriters a 30 day option to purchase up to an additional 3,450,000 shares of common stock to cover over-allotments, if any.
- GlobeNewswire•yesterday
Sunesis Announces Proposed Public Offering of Common Stock and Preferred Stock
Sunesis Pharmaceuticals, Inc. (SNSS) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock and Series E Convertible Preferred Stock in underwritten public offerings. There can be no assurance as to whether or when the proposed offerings may be completed, or as to the actual size or terms of the offerings. Sunesis also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock offered in the public offering to cover over-allotments, if any. Sunesis anticipates using the net proceeds from the proposed offerings to fund ongoing development of vecabrutinib, ongoing research and development, debt amortization, and general corporate purposes.
- GlobeNewswire•17 days ago
Sunesis Pharmaceuticals Announces Advancement into 100mg Cohort of Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies
Sunesis Pharmaceuticals, Inc. (SNSS) today announced that the Company has opened the 100 mg cohort in the Phase 1b/2 trial of its non-covalent BTK inhibitor vecabrutinib in adults with relapsed/refractory chronic lymphocytic leukemia (CLL) and other B-cell malignancies. “Thus far, we have seen an encouraging safety profile, evidence of pharmacodynamic activity in CLL and other B cell cancer patients both with and without BTK C481 mutations, and some improvements in clinical symptoms. Vecabrutinib (SNS-062) is a selective, oral, reversible, non-covalent inhibitor of Bruton's tyrosine kinase (BTK).
- Thomson Reuters StreetEvents•last month
Edited Transcript of SNSS earnings conference call or presentation 5-Nov-18 9:30pm GMT
Q3 2018 Sunesis Pharmaceuticals Inc Earnings Call
- Benzinga•2 months ago
The Daily Biotech Pulse: ASH Presentations Take The Spotlight, Eiger Gets A New CFO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 3) Abbott Laboratories (NYSE: ABT ) AEterna Zentaris Inc. ...
- GlobeNewswire•2 months ago
Sunesis Pharmaceuticals Announces Presentation of Preliminary Data from Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies at ASH Annual Meeting
Sunesis Pharmaceuticals, Inc. (SNSS) today announced the presentation of results from the Company’s Phase 1b/2 clinical trial of its non-covalent BTK inhibitor vecabrutinib in adults with relapsed/refractory chronic lymphocytic leukemia (CLL) and other B-cell malignancies. The results will be presented today, December 2, from 6:00-8:00 p.m. PT in a poster session titled “CLL: Therapy, excluding Transplantation: Poster II” at the 60th American Society of Hematology (ASH) Annual Meeting in San Diego, California. “To date, vecabrutinib has demonstrated both an encouraging safety profile and evidence of pharmacodynamic activity in CLL and other B cell cancer patients both with and without the BTK C481 mutation,” said Dayton Misfeldt, Sunesis interim Chief Executive Officer.
- Zacks•2 months ago
Zacks.com highlights: Asbury Automotive, OncoGenex Pharmaceuticals, aTyr Pharma, Avinger and Sunesis Pharmaceuticals
Zacks.com highlights: Asbury Automotive, OncoGenex Pharmaceuticals, aTyr Pharma, Avinger and Sunesis Pharmaceuticals
- Zacks•2 months ago
5 Top-Ranked Rising P/E Stocks to Lure Investors
Inside the top-ranked stocks that have been exhibiting rising P/E ratios.
- GlobeNewswire•2 months ago
Sunesis Pharmaceuticals to Provide Program Update for Non-Covalent BTK-Inhibitor Vecabrutinib at Analyst & Investor Event during ASH 2018
Sunesis Pharmaceuticals, Inc. (SNSS) today announced it will provide a program update for vecabrutinib, the Company’s oral, reversible, non-covalent, BTK inhibitor which is currently being evaluated in an ongoing Phase 1b/2 clinical trial in adults with relapsed chronic lymphocytic leukemia (CLL) and other B-cell malignancies. Sunesis’ executive management team will present an update on vecabrutinib from the ongoing Phase 1b/2 dose-escalation study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of vecabrutinib in B-lymphoid malignancy patients with prior BTK therapy. The Phase 1b/2 trial is an open-label, sequential-group study that is enrolling patients across eight leading sites in the United States.
- GlobeNewswire•2 months ago
Report: Developing Opportunities within NeuroMetrix, Sunesis Pharmaceuticals, Siga Technologies, NexPoint Residential Trust, Frequency Electronics, and Horizon Technology Finance — Future Expectations, Projections Moving into 2018
NEW YORK, Nov. 15, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Associated Press•2 months ago
Sunesis: 3Q Earnings Snapshot
On a per-share basis, the South San Francisco, California-based company said it had a loss of 18 cents. In the final minutes of trading on Monday, the company's shares hit $1.32. A year ago, they were ...
- GlobeNewswire•2 months ago
Sunesis Pharmaceuticals Reports Third Quarter 2018 Financial Results and Recent Highlights
Sunesis to Host Conference Call Today at 4:30 PM Eastern Time SOUTH SAN FRANCISCO, Calif., Nov. 05, 2018 -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported.
- GlobeNewswire•3 months ago
Sunesis Pharmaceuticals Announces Presentations at 60th American Society of Hematology Annual Meeting
SOUTH SAN FRANCISCO, Calif., Nov. 01, 2018 -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced two poster presentations and an oral presentation at the 60th.
- GlobeNewswire•3 months ago
Sunesis Pharmaceuticals to Host Conference Call on November 5th to Discuss Third Quarter 2018 Financial Results and Recent Highlights
Sunesis Pharmaceuticals, Inc. (SNSS) today announced that it will host a conference call on Monday, November 5th, 2018 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results for the third quarter ended September 30, 2018. To access the live audio webcast, or the subsequent archived recording, visit the "Investors and Media - Calendar of Events" section of the Sunesis website at http://ir.sunesis.com. The webcast will be recorded and available for replay on the company's website for two weeks.
- Simply Wall St.•4 months ago
Should You Worry About The Sunesis Pharmaceuticals Inc’s (NASDAQ:SNSS) Shareholder Register?
A look at the shareholders of Sunesis Pharmaceuticals Inc (NASDAQ:SNSS) can tell us which group is most powerful. Generally speaking, as a company grows, institutions will increase their ownership. Conversely,Read More...
- Thomson Reuters StreetEvents•4 months ago
Edited Transcript of SNSS earnings conference call or presentation 7-Aug-18 8:30pm GMT
Q2 2018 Sunesis Pharmaceuticals Inc Earnings Call
- Associated Press•5 months ago
Sunesis: 2Q Earnings Snapshot
The South San Francisco, California-based company said it had a loss of 20 cents per share. In the final minutes of trading on Tuesday, the company's shares hit $2.45. A year ago, they were trading at ...
